27
Participants
Start Date
February 10, 2017
Primary Completion Date
May 30, 2019
Study Completion Date
May 29, 2020
Recombinant Humanized Monoclonal Antibody MIL62 Injection
The patients confirming to the eligibility criteria will be assigned to the 5 dose groups (200mg, 400mg, 800mg, 1000mg, and 1500mg, respectively) based on the sequence of inclusion. Each patient received an intravenous infusion of MIL62 on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2-8 for a maximum of 8 cycles and 10 infusions. Each cycle was 21 days.
Chinese Academy of Medical Sciences (CAMS) & Peking Union Medical College (PUMC), Beijing
Beijing Mabworks Biotech Co., Ltd.
INDUSTRY